Ken Keller is joining Daiichi Sankyo Inc. as president of U.S. commercial operations.


Daiichi Sankyo, Ken Keller, president of U.S. commercial operations, Spectrum Pharmaceuticals, Joji Nakayama, Glenn Gormley, Daiichi Sankyo Group, Greg Barrett


































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Daiichi Sankyo appoints U.S. commercial president

April 21st, 2014

PARSIPPANY, N.J. – Ken Keller is joining Daiichi Sankyo Inc. as president of U.S. commercial operations.

The pharmaceutical company said Keller is due to start in the position on May 1 and will be responsible for leading marketing, sales, medical affairs and supply chain operations for Daiichi Sankyo in the United States.

Previously, Keller was executive vice president and chief operating officer at Spectrum Pharmaceuticals, where he oversaw global commercial, medical, research and development, and manufacturing. Daiichi Sankyo noted that he also was responsible for business development at Spectrum and was integral to the acquisition and integration of Talon Therapeutics into the company. Before Spectrum, Keller spent 21 years at Amgen, most recentlt as as vice president and general manager for tthe bone health and inflammation business units and as managing director at Amgen Ltd. in the United Kingdom and Ireland.

"We are very pleased to welcome Ken Keller into the Daiichi Sankyo family," stated Joji Nakayama, president and chief executive officer of Daiichi Sankyo Co. Ltd., the parent of Daiichi Sankyo Group. "Ken brings with him more than 25 years of pharmaceutical experience, with career highlights including building a $3 billion business unit as well as leading commercialization for four of the world's top selling biologic medicines. His broad experience and proven success will be a tremendous asset to Daiichi Sankyo."

Daiichi Sankyo said that with Keller's appointment, Glenn Gormley will assume the role of executive chairman and president of Daiichi Sankyo Inc. and will retain his roles as president of Daiichi Sankyo Pharma Development and as the global head of research and development for Daiichi Sankyo Co. Ltd. Greg Barrett, who served as interim president of U.S. commercial operations for the past seven months, will remain vice president of marketing and managed markets at Daiichi Sankyo Inc.

Advertisement